Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin
| Autor: | Fiona Russell-Yarde, Paul Jordan, Adam J Foley-Comer, Anne-Marie Young |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty Statin Adolescent medicine.drug_class Atorvastatin Cmax Thiophenes Pharmacology chemistry.chemical_compound Young Adult Pharmacokinetics Internal medicine medicine Humans Pharmacology (medical) Rosuvastatin Drug Interactions PPAR alpha Pyrroles cardiovascular diseases Rosuvastatin Calcium Oxazoles Aged Sulfonamides Aleglitazar Cross-Over Studies business.industry nutritional and metabolic diseases General Medicine Middle Aged Crossover study Fluorobenzenes PPAR gamma Endocrinology Pyrimidines chemistry Heptanoic Acids Area Under Curve lipids (amino acids peptides and proteins) Female Hydroxymethylglutaryl-CoA Reductase Inhibitors business medicine.drug |
| Zdroj: | Expert opinion on investigational drugs. 20(1) |
| ISSN: | 1744-7658 |
| Popis: | Aleglitazar, a dual PPAR-α/γ agonist, combines the lipid benefits of fibrates and the insulin-sensitizing benefits of thiazolidinediones.To investigate the pharmacokinetic effects of co-administration of atorvastatin or rosuvastatin with aleglitazar.In a two-cohort, open-label, randomised, three-period crossover study, 44 healthy subjects received once-daily oral doses of aleglitazar 300 μg, statin (atorvastatin 80 mg or rosuvastatin 40 mg) and aleglitazar co-administered with each statin for 7 days. Plasma concentrations of each drug were measured and pharmacokinetic parameters determined on day 7 in each period.Peak observed plasma concentration (C(max)) and total exposures (AUC(0 - 24)) of aleglitazar, atorvastatin and rosuvastatin.C(max) and AUC(0 - 24) to aleglitazar were similar, whether administered alone or in combination with a statin. Total exposure to either statin was unaffected by co-administration with aleglitazar. C(max) treatment ratios for both statins exceeded the conventional no-effect boundary (1.25) when administered with aleglitazar.Co-administration of aleglitazar with a statin does not alter the pharmacokinetic profile of either drug. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|